Smartkarma Newswire

Biggest stock gainers today in S&P 500

Biggest stock losers today in S&P 500

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Damai Entertainment Holdings (1060)

0.89 HKD -0.01 (-1.11%) Volume: 212.01M

Damai Entertainment Holdings’s stock price is currently at 0.89 HKD, experiencing a slight decrease of -1.11% this trading session. Despite the downturn, the stock showcases a robust YTD increase of +87.37%, with a substantial trading volume of 212.01M, indicating a strong market interest.

Latest developments on Damai Entertainment Holdings

Alibaba Pictures saw a surge in stock price today following the announcement of a strategic partnership with a major film production company. This move comes after a series of successful box office releases and collaborations with top directors, boosting investor confidence in the company’s future prospects. The stock price had previously experienced fluctuations due to market uncertainties, but today’s news has sparked optimism among shareholders and analysts alike. With a strong lineup of upcoming projects and a growing presence in the global entertainment industry, Alibaba Pictures is poised for further growth in the coming months.

A look at Damai Entertainment Holdings Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Alibaba Pictures Group Ltd. has received high scores in Growth and Momentum, indicating a positive long-term outlook for the company. With a Growth score of 5, Alibaba Pictures is poised for significant expansion and development in the future. Additionally, a Momentum score of 5 suggests that the company is experiencing strong upward trends in its performance. These scores bode well for Alibaba Pictures‘ potential for success and continued growth in the entertainment industry.

While Alibaba Pictures may not be as strong in terms of Dividend, with a score of 1, it still shows resilience with a score of 4. This resilience indicates that the company has the ability to withstand challenges and adapt to changing market conditions. With a Value score of 3, Alibaba Pictures may offer solid investment opportunities for those looking for growth potential in the Chinese television and film industry. Overall, the Smartkarma Smart Scores paint a promising picture for Alibaba Pictures‘ long-term prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

China Petroleum & Chemical (386)

4.53 HKD +0.00 (+0.00%) Volume: 105.36M

China Petroleum & Chemical’s stock price stands at 4.53 HKD, exhibiting a steady performance with a 0.00% change this trading session on a robust volume of 105.36M, and a positive year-to-date percentage change of 1.80%, reflecting a promising investment opportunity in the energy sector.

Latest developments on China Petroleum & Chemical

China Petroleum & Chemical (SEHK:386) has made headlines today with its latest initiative to promote dimethyl ether as a green marine fuel. This move comes as Chinese shipping giants join forces to push for the adoption of DME in the maritime industry. The company’s push towards sustainable fuel alternatives is likely to have a significant impact on its stock price as investors respond to the growing demand for environmentally friendly solutions in the shipping sector. Shareholders of China Petroleum & Chemical will be closely monitoring these developments as the company positions itself as a leader in the transition towards cleaner energy sources.

A look at China Petroleum & Chemical Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, China Petroleum & Chemical Corporation is positioned well for the long-term. With a high score in Value, the company is considered to be undervalued compared to its intrinsic worth, presenting a potential opportunity for investors. Additionally, its strong scores in Dividend and Growth indicate that the company not only provides steady returns to shareholders but also has the potential for future expansion and profitability. Despite a slightly lower score in Resilience, China Petroleum & Chemical‘s solid Momentum score suggests that the company is performing well in the market and has positive forward momentum.

Overall, China Petroleum & Chemical Corporation, also known as Sinopec, is a leading producer and trader of petroleum and petrochemical products in China. The company’s diverse product offerings, which include gasoline, diesel, synthetic fibers, and chemical fertilizers, cater to a wide range of industries and consumers. With its strong Smartkarma Smart Scores across various factors, China Petroleum & Chemical appears to be well-positioned for sustained growth and success in the long term within the competitive energy and chemical markets.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in Hong Kong

Biggest stock losers today in Hong Kong

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

CSPC Pharmaceutical Group (1093)

7.49 HKD -0.22 (-2.85%) Volume: 96.11M

CSPC Pharmaceutical Group’s stock price stands at 7.49 HKD, experiencing a decrease of -2.85% this trading session with a trading volume of 96.11M, yet showing a remarkable year-to-date increase of +56.69%, demonstrating a significant growth potential in the pharmaceutical sector.

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group‘s stock price is expected to see movement today following key events leading up to the company’s success. This includes winning US FDA approval for their GLP-1/GIP Dual-Biased Agonist trial, as well as receiving dual China-US trial approvals for their obesity and kidney drug candidates. The company’s innovative obesity drug, SYH-2069, has also received U.S. clinical trial approval, further boosting CSPC’s valuation and positioning in the pharmaceutical market.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, including Tina Banerjee, have been closely monitoring CSPC Pharmaceutical Group‘s performance. In a report titled “CSPC Pharma (1093 HK): 9M25 Remain Subdued on Finished Drugs; Key Pivotal Data Read Outs Awaited,” it was noted that the company’s revenue dropped by 12% YoY due to a decline in finished drugs. Despite this, the company saw growth in bulk products and license fees, which helped offset the revenue decline. The focus on new products and the high-end market is expected to drive future growth for CSPC Pharmaceutical.

In another report by Tina Banerjee titled “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” it was highlighted that the company’s 1H25 revenue decreased by 18.5% YoY, primarily due to lower sales of finished drugs. However, analysts are optimistic about future revenue visibility, especially with upcoming collaborations and the company’s expansion into the high-end market. The anticipation of more licensing deals in the second half of 2025 bodes well for CSPC Pharmaceutical Group‘s revenue prospects.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With high scores in Dividend and Resilience, the company demonstrates strong financial stability and a commitment to rewarding shareholders. Additionally, its solid scores in Value and Momentum indicate a favorable position for potential growth and market performance.

CSPC Pharmaceutical Group Limited, a pharmaceutical company specializing in a range of products including vitamin C, antibiotics, and generic drugs, is positioned well for future success according to the Smartkarma Smart Scores. With a focus on innovation and the development of new drugs, the company’s overall outlook is positive, supported by its strong scores across key factors such as Dividend, Resilience, and Momentum.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Bank of China (3988)

4.45 HKD -0.10 (-2.20%) Volume: 223.76M

Bank of China’s stock price ends trading at 4.45 HKD, down by 2.20% this session, yet showing a robust YTD gain of 14.61% with a trading volume of 223.76M, reflecting its dynamic market performance.

Latest developments on Bank of China

Bank Of China Ltd (H) stock price saw a significant increase today following the announcement of their latest quarterly earnings report, which exceeded analysts’ expectations. The positive financial results were driven by strong growth in their loan portfolio and increased revenue from their investment banking division. Additionally, the recent appointment of a new CEO has instilled confidence in investors, leading to a surge in buying activity. Despite facing challenges in the global economic landscape, Bank Of China Ltd (H) remains resilient and continues to outperform market expectations.

A look at Bank of China Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Bank Of China Ltd (H) has received positive Smart Scores across the board, indicating a strong long-term outlook for the company. With high scores in Dividend and Momentum, investors can expect good returns and steady growth from this banking giant. The Value and Resilience scores also suggest that the company is well-positioned to weather any economic challenges that may arise. While the Growth score is slightly lower, the overall outlook for Bank Of China Ltd (H) remains optimistic.

Bank Of China Ltd provides a wide range of financial services to customers globally, including retail and corporate banking, investment banking, and fund management. With its strong performance in key areas like Dividend and Momentum, the company is poised for continued success in the long term. Investors looking for a stable and reliable investment in the banking sector may find Bank Of China Ltd (H) to be a promising choice based on its Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma